VANGUARD HEALTH CARE INDEX FUND
VANGUARD WORLD FUND · Series S000004450 · 2 share classes
data updated 2026-09-08
Fund profile
As filed in the prospectus · 2026 Q2
Vanguard Health Care Index Fund (the Fund) seeks to track the performance of a benchmark index that measures the investment return of health care stocks.
The fund tracks the MSCI US Investable Market Index (IMI)/Health Care 25/50 by holding all or substantially all of the stocks in the index in the same proportions, gaining exposure to large, mid-size, and small U.S. health care companies including providers, equipment manufacturers, and pharmaceutical and biotechnology firms. Because the fund attempts to replicate the index rather than sample it, tracking error may arise from the fund's holdings diverging from index weightings.
| Share class | Expense ratio |
|---|---|
| VHCIX | 0.09% |
| VHT | 0.09% |
Portfolio turnover 4.00% · as of 2026 Q2
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.80% |
| Cash & short-term | 0.22% |
| Derivatives | -0.00% |
The outer band is exposure held short — written against the portfolio rather than part of it, which is why it sits outside the ring and why the two are never netted into one figure.
Derivatives are shown at market value, not notional exposure.
Latest quarter
What changed since the fund's previous filing
Largest new: AGL, TRAX, Hologic Inc
Largest exited: Exact Sciences Corp, Hologic Inc, Amicus Therapeutics Inc, Arcellx Inc, Terns Pharmaceuticals Inc, Soleno Therapeutics Inc, Apellis Pharmaceuticals Inc, Ventyx Biosciences Inc
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| +8.25% | +16.20% | +23.17% | 15.88% | -14.94% | |
| +8.25% | +16.20% | +23.13% | 15.88% | -14.94% |
These classes hold the same portfolio, so the 0.04pp spread over 5 years is the cost difference between them — roughly 0.01pp a year — not a difference in what they own.
May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| LLY | Eli Lilly & CoLLY | 14.04% | $1,105.00 | $2.67B | 2.4M |
| JNJ | Johnson & JohnsonJNJ | 8.47% | $225.33 | $1.61B | 7.1M |
| ABBV | AbbVie IncABBV | 6.09% | $217.72 | $1.16B | 5.3M |
| UNH | UnitedHealth Group IncUNH | 5.45% | $380.31 | $1.03B | 2.7M |
| MRK | Merck & Co IncMRK | 4.66% | $118.72 | $885.00M | 7.5M |
| TMO | Thermo Fisher Scientific IncTMO | 2.93% | $492.51 | $555.74M | 1.1M |
| AMGN | Amgen IncAMGN | 2.87% | $336.79 | $544.66M | 1.6M |
| GILD | Gilead Sciences IncGILD | 2.64% | $134.43 | $500.92M | 3.7M |
| ISRG | Intuitive Surgical IncISRG | 2.38% | $424.64 | $452.10M | 1.1M |
| ABT | Abbott LaboratoriesABT | 2.35% | $85.60 | $447.02M | 5.2M |
Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.
Top 10 positions are 51.88% of net assets, top 25 73.33%, across 402 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free